The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index; 27 of the 57 sources its claims cite were checked for support.
The European Biological Variation Study (EuBIVAS): a summary report
Open accessAbstract
Biological variation (BV) data have many important applications in laboratory medicine. Concerns about quality of published BV data led the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) 1st Strategic Conference to indicate need for new studies to generate BV estimates of required quality. In response, the EFLM Working Group on BV delivered the multicenter European Biological Variation Study (EuBIVAS). This review summarises the EuBIVAS and its outcomes. Serum/plasma samples were taken from 91 ostensibly healthy individuals for 10 consecutive weeks at 6 European centres. Analysis was performed by Siemens ADVIA 2400 (clinical chemistry), Cobas Roche 8000, c702 and e801 (proteins and tumor markers/hormones respectively), ACL Top 750 (coagulation parameters), and IDS iSYS or DiaSorin Liaison (bone biomarkers). A strict preanalytical and analytical protocol was applied. To determine BV estimates with 95% CI, CV-ANOVA after analysis of outliers, homogeneity and trend analysis or a Bayesian model was applied. EuBIVAS has so far delivered BV estimates for 80 different measurands. Estimates for 10 measurands (non-HDL cholesterol, S100-β protein, neuron-specific enolase, soluble transferrin receptor, intact fibroblast growth-factor-23, uncarboxylated-unphosphorylated matrix-Gla protein, human epididymis protein-4, free, conjugated and %free prostate-specific antigen), prior to EuBIVAS, have not been available. BV data for creatinine and troponin I were obtained using two analytical methods in each case. The EuBIVAS has delivered high-quality BV data for a wide range of measurands. The BV estimates are for many measurands lower than those previously reported, having an impact on the derived analytical performance specifications and reference change values.
Overview
CoChat Summary
TL;DR
The EuBIVAS multicenter study collected weekly serum/plasma samples from 91 ostensibly healthy individuals over 10 consecutive weeks at six European centers to generate high-quality biological variation (BV) estimates. It has delivered BV estimates for 80 measurands, including 10 previously unavailable, with many estimates lower than historical data and implications for analytical performance specifications (APS) and reference change values (RCVs).
Key findings
- EuBIVAS delivered BV estimates for 80 measurands; 10 had no prior published estimates: non-HDL cholesterol, S100β protein, neuron-specific enolase, soluble transferrin receptor, intact fibroblast growth-factor-23, uncarboxylated-unphosphorylated matrix-Gla protein, human epididymis protein-4, and free, conjugated and %free prostate-specific antigen.
- For many measurands, EuBIVAS BV estimates were lower than previously reported, producing stricter APS and smaller RCVs; for common measurands such as albumin, creatinine, urea, chloride, sodium, potassium, lipids and glucose, EuBIVAS did not really change prior estimates.
- About 25% of participants had at least one mild inflammation episode during the 10 weeks; exclusions for proteins ranged from 4.9% for β2-microglobulin to 20% for haptoglobin. For 25(OH)D, no steady state was found; concentrations increased by 2.8% weekly over spring and by 31.6% after 10 weeks, with proposed measurement uncertainty thresholds of <1.2% for higher-order reference methods and <13.6% for routine assays to detect an increase at p<0.05 (9.6% at p<0.01).
- EuBIVAS is fully BIVAC compliant and elicited grade A; systematic reviews found only 3/61 kidney-related, 1/59 lipid, 1/47 diabetes-related, 6/16 cardiac troponin and 4/49 tumor marker papers fully BIVAC compliant, with all A-graded tumor marker publications derived from EuBIVAS.
Methods
- Multicenter study at six European laboratories (Milan, Bergen, Madrid, Padua, Istanbul, Assen); 105 subjects were recruited, 97 volunteers were sampled, and the final CV-ANOVA population was 91 subjects (38 men, 43 women in fertile age, 10 women above 50 years identified as menopausal). Fasting blood samples were drawn weekly for 10 consecutive weeks (April–June 2015), providing serum, K2EDTA-plasma and citrated-plasma samples; a biobank of 18,000 aliquots was established.
- Analyses used Siemens ADVIA 2400 (clinical chemistry), Cobas Roche 8000 c702 and e801 (proteins and tumor markers/hormones), ACL Top 750 (coagulation parameters), and IDS iSYS or DiaSorin Liaison (bone biomarkers); all samples from the same participant were analyzed in duplicate within a single run under a strict preanalytical and analytical protocol.
- BV estimates were mostly obtained by the Røraas method based on CV-ANOVA after outlier, homogeneity and trend analysis; a Bayesian approach was applied for coagulation parameters. CVG was calculated on natural log-transformed data, RCVs used the log-normal approach, and subgroup analyses were performed by sex, age and country where relevant.
Limitations
- Stated by the authors: the small number of menopausal women (n=10) is an undoubted limitation; estimates from women >50 years were not used for APS calculations, and if significant differences exist between pre- and postmenopausal women, estimates from this small subgroup may not reliably characterize them.
- Stated by the authors: the classical BV model was inappropriate for 25(OH)D and inflammatory marker proteins; for 25(OH)D more than 50% of data were eliminated, and after MoM transformation more than 40% were still eliminated, while high exclusions for proteins such as haptoglobin may have limited generalizability and caused underestimation of BV.
- Stated by the authors: most available BV data are derived from healthy adults, and further studies are required for children, elderly and patients with relevant disease states. Evident from the text: as a summary report, detailed per-measurand methods and results are deferred to prior EuBIVAS publications.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
18 Valid · 2 Not valid · 20 Not checked · 48 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The second finding from EuBIVAS is that, for some measurands, significant differences between mean BV estimates were found in subgroups e.g., males/females; menopausal/fertile women; or for other occasional subgroups (e.g. for creatinine [24] and thyroid hormones [35], for which the country of origin was considered).”
What the sources say
- Not checked — no full text of the sourcecites [24] Carobene, A, Marino, I, Coŝkun, A, Serteser, M, Unsal, I, Guerra, E, et al.. The EuBIVAS project: within and between-subject biological variation data for serum creatinine using enzymatic and alkaline picrate methods and implications for monitoring. Clin Chem 2017;63:1527–36. https://doi.org/10.1373/clinchem.2017.275115. source
- Disputedcites [35] Bottani, A, Aarsand, AK, Banfi, G, Locatelli, M, Coşkun, A, Díaz-Garzón, J, et al.. European Biological Variation Study (EuBIVAS): within- and between-subject biological variation estimates for serum thyroid biomarkers based on weekly samplings from 91 healthy participants. Clin Chem Lab Med 2022;60:523–32. https://doi.org/10.1515/cclm-2020-1885. sourceExperimental — accuracy not yet measured
The Conclusions (page unavailable) state that thyroid-marker within-subject BV estimates did not differ between countries or between men and women. The Results report country-specific differences in TSH and thyroglobulin concentrations, not BV estimates, and no BV differences between the fertile-age and menopausal female subgroups. Thus this paper contradicts the subgroup BV differences attributed to it for thyroid markers. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Interestingly, the data indicate that for the most common measurands routinely measured in the clinical laboratories, EuBIVAS data did not really change the prior estimates, as displayed by Jonker et al. for albumin, creatinine, urea, chloride, sodium and potassium [44].”
- Also stated in: § EuBIVAS outcomes · p. 7 · boosted
“This is also demonstrable from the work of Díaz-Garzón et al. [45] for total, HDL and LDL cholesterol and for triglycerides, and by González-Lao et al. for glucose [46].”
What the sources say
- Disputedcites [44] Jonker, N, Aslan, B, Boned, B, Marqués-García, F, Ricós, C, Alvarez, V, et al.. Critical appraisal and meta-analysis of biological variation estimates for kidney related analytes. Clin Chem Lab Med 2022;60:469–78. https://doi.org/10.1515/cclm-2020-1168. sourceExperimental — accuracy not yet measured
The paper’s Content and Summary passages (page unavailable in our copy) say its updated biological-variation estimates were lower than previously reported estimates for all the listed kidney measurands except urea. That contradicts the claim that the estimates did not really change. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [45] Díaz-Garzón, J, Fernández-Calle, P, Minchinela, J, Aarsand, AK, Bartlett, WA, Aslan, B, et al.. Biological variation data for lipid cardiovascular risk assessment biomarkers. A systematic review applying the biological variation data critical appraisal checklist (BIVAC). Clin Chim Acta 2019;495:467–75. https://doi.org/10.1016/j.cca.2019.05.013. sourceExperimental — accuracy not yet measured
The Discussion says the paper’s updated biological-variation estimates for lipids were of the same order as those in the online 2014 database, supporting the claim for total, HDL and LDL cholesterol and triglycerides. The comparison is from this paper’s meta-analysis, however, not identified as EuBIVAS data; the paper does not establish the claimed comparison for albumin, creatinine, urea, chloride, sodium, potassium or glucose. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [46] González-Lao, E, Corte, Z, Simón, M, Ricós, C, Coskun, A, Braga, F, et al.. Systematic review of the biological variation data for diabetes related analytes. Clin Chim Acta 2019;488:61–7. https://doi.org/10.1016/j.cca.2018.10.031. source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § EuBIVAS outcomes · p. 7 · boosted
Every source the paper cites for this claim was checked and supports it.
In the paper
“four out of 49 for tumor markers.”
What the sources say
- Supportedcites [48] Marqués-García, F, Boned, B, González-Lao, E, Braga, F, Carobene, A, Coskun, A, et al.. Critical review and meta-analysis of biological variation estimates for tumor markers. Clin Chem Lab Med 2022;60;494–504. source
The Results report that the systematic review identified 49 tumor-marker studies and that BIVAC appraisal gave four papers grade A. The Quality and study characteristics section describes those four as receiving the highest quality grade, supporting the claim's use of “fully BIVAC compliant.” (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“one out of 59 for lipid biomarkers of cardiovascular risk [45]”
What the sources say
- Supportedcites [45] Díaz-Garzón, J, Fernández-Calle, P, Minchinela, J, Aarsand, AK, Bartlett, WA, Aslan, B, et al.. Biological variation data for lipid cardiovascular risk assessment biomarkers. A systematic review applying the biological variation data critical appraisal checklist (BIVAC). Clin Chim Acta 2019;495:467–75. https://doi.org/10.1016/j.cca.2019.05.013. source
The Results report 59 publications with biological-variation data for the lipid measurands, of which one received a BIVAC grade of A. The Material and methods section defines A as the highest compliance grade, supporting the description of that one paper as fully compliant. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“For the tumor markers, all A-graded publications were derived from the EuBIVAS [48].”
What the sources say
- Supportedcites [48] Marqués-García, F, Boned, B, González-Lao, E, Braga, F, Carobene, A, Coskun, A, et al.. Critical review and meta-analysis of biological variation estimates for tumor markers. Clin Chem Lab Med 2022;60;494–504. source
The Limitations section states that only four papers published by the EuBIVAS group received a BIVAC A grade. The Quality and study characteristics section likewise says that all four highest-grade tumor-marker studies were derived from EuBIVAS. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
47 more claims · 10 with their cited sources checked
Create a free account to see all 88 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 27
- Probably not a substantial claim. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, the EFLM biological variation working group (BV-WG) set up the European Biological Variation Study (EuBIVAS) project, a multicenter study that collected samples from five different European countries using a stringent pre-analytical protocol and robust statistical techniques [ 155 ] and updated the BV data of numerous analytes [ 156 ].”
From Physiological Rhythms and Biological Variation of Biomolecules: The Road to Personalized Laboratory Medicine (2023) · cites this paper as [156]
Citations
Cites
Current databases on biological variation: pros, cons and progress
C. Ricós, V. A. (1999) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365519950185229 · Cited by 987 · cited 4×
“characteristics of the populations studied in the papers included in the historical estimates varied and include diseased (uncomplicated myocardial infarction, liver disease, type 1 diabetes mellitus) and non-diseased subjects [12, 16].”
BackgroundMethodInfluentialSandberg, S., Fraser, C. G., Horvath, A. R., Jansen, R., Jones, G., Oosterhuis, W., Petersen, P. H., Schimmel, H., Sikaris, K., & Panteghini, M. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-0067 · Cited by 563
Self-citationAarsand, A. K., Røraas, T., Fernandez-Calle, P., Ricos, C., Díaz-Garzón, J., Jonker, N., Perich, C., González-Lao, E., Carobene, A., Minchinela, J., et al. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.281808 · Cited by 233
Self-citationAnalytical performance characteristics should be judged against objective quality specifications
Fraser, C. G., & Petersen, P. H. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.3.321 · Cited by 194
Ceriotti, F., Fernandez-Calle, P., Klee, G. G., Nordin, G., Sandberg, S., Streichert, T., Vives-Corrons, J.-L., & Panteghini, M. (2017) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-0091 · Cited by 181
Self-citationIntroduction: Strategies to set global quality specifications in laboratory medicine
C. G. Fraser, A. K. (1999) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365519950185184 · Cited by 172
A checklist for critical appraisal of studies of biological variation
Bartlett, W. A., Braga, F., Carobene, A., Coşkun, A., Prusa, R., Fernandez-Calle, P., Røraas, T., Jonker, N., Sandberg, S., & Variati, O. B. O. T. B. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-1127 · Cited by 151 · cited 3×
“Examination of the data revealed that there was no steady state in 25(OH)D concentrations across time, a necessary pre-requisite for the BV estimates derivation [19, 41].”
BackgroundMethodSelf-citationRøraas, T., Petersen, P. H., & Sandberg, S. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2012.187781 · Cited by 134 · cited 1×
“Firstly, it is sufficiently powered [43] to enable subgroup analysis.”
BackgroundSelf-citationRøraas, T., Støve, B., Petersen, P. H., & Sandberg, S. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2015.252296 · Cited by 129
Self-citationCoşkun, A., Sandberg, S., Unsal, I., Cavusoglu, C., Serteser, M., Kilercik, M., & Aarsand, A. K. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvaa233 · Cited by 112 · cited 1×
“The data can be used to establish reference change values (RCV) that enable objective assessment of significance of change in serial test results [6, 7], to estimate the number of samples required to calculate the homeostatic set point (NHSP) [7, 8], to assess the utility of conventional population-based reference int…”
MethodSelf-citation
Research works printed but not linked: 2
- Fraser, CG. The nature of biological variation. In: biological variation: from principles to practice. Washington, DC: AACC Press; 2001:1–27 pp.
- Fraser, CG. Biological variation in clinical chemistry. Arch Pathol Lab Med 1992;116:916–23.
Cited by
Biological variation estimates of Alzheimer's disease plasma biomarkers in healthy individuals
Brum, W. S., Ashton, N. J., Simrén, J., Molfetta, G. D., Karikari, T. K., Benedet, A. L., Zimmer, E. R., Lantero‐Rodriguez, J., Montoliu‐Gaya, L., Jeromin, A., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13518 · Cited by 80
“37,38”
MethodSelf-citationClinlabomics: leveraging clinical laboratory data by data mining strategies
Wen, X., Leng, P., Wang, J., Yang, G., Zu, R., Jia, X., Zhang, K., Mengesha, B. A., Huang, J. H., Wang, D., et al. (2022) · BMC Bioinformatics · doi:10.1186/s12859-022-04926-1 · Cited by 81
Coskun, A., Zarepour, A., & Zarrabi, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076275 · Cited by 61
“Recently, the EFLM biological variation working group (BV-WG) set up the European Biological Variation Study (EuBIVAS) project, a multicenter study that collected samples from five different European countries using a stringent pre-analytical protocol and robust statistical techniques [155] and updated the BV data of…”
MethodPersonalized reference intervals: from theory to practice
Coşkun, A., Sandberg, S., Ünsal, İ., Serteser, M., & Aarsand, A. K. (2022) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2022.2070905 · Cited by 66
“The EFLM Biological Variation Working Group (BVWG) designed and performed the European Biological Variation Study (EuBIVAS), a multi-center study collecting samples from more than 90 participants from five European countries [84,85], and has provided updated BV data for a large number of measurands [85].”
MethodSelf-citationBiological variation: recent development and future challenges
Sandberg, S., Carobene, A., Bartlett, W. A., Coşkun, A., Fernández–Calle, P., Jonker, N., Díaz–Garzón, J., & Aarsand, A. K. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-1255 · Cited by 65
Self-citation
Metadata
- Authors
- Carobene, A., Aarsand, A. K., Bartlett, W. A., Coskun, A., Diaz-Garzon, J., Fernandez-Calle, P., Guerra, E., Jonker, N., Locatelli, M., Plebani, M., Sandberg, S., & Ceriotti, F.
- Affiliations
- IRCCS Ospedale San Raffaele (IT)
- Haukeland University Hospital (NO)
- University of Dundee (GB)
- Acibadem Mehmet Ali Aydınlar University, School of Medicine , Istanbul , Turkey
- Hospital Universitario La Paz, and Quality Analytical Commission of Spanish Society of Laboratory Medicine (SEQC ) , Madrid , Spain
- Stichting Certe Medische Diagnostiek en Advies (NL)
- University of Padua (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Corresponding author
- Carobene, Anna
- ORCID
- Venue
- Clinical Chemistry and Laboratory Medicine (CCLM)
- Publisher
- Walter de Gruyter GmbH
- Published
- 2021-05-31
- Volume
- 60
- Issue
- 4
- Pages
- 505-517
- ISSN
- 1434-6621 (ISSN-L)
- 1437-4331
- OpenAlex
- W3165813453
- Cited by
- 84
- References
- 48
- Citations by year
- 2026: 12 · 2025: 12 · 2024: 18 · 2023: 16 · 2022: 17 · 2021: 9
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Chemistry and Laboratory Medicine (CCLM) (publishedVersion)
- PubMed (publishedVersion)
- Acibadem University Open Access Repository (submittedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion, other-oa)
- NORA - Norwegian Open Research Archives (submittedVersion, other-oa)
- Topics
- Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
- Physical Sciences › Physics and Astronomy › Instrumentation › Scientific Measurement and Uncertainty Evaluation
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Reliability and Agreement in Measurement
- Keywords
- biological variation, reference values, healthy volunteers, Bayesian model, reference change value, analytical performance specifications, tumor markers, bone turnover markers, coagulation parameters, prostate-specific antigen, fibroblast growth factor 23, matrix Gla protein, creatinine, troponin I
- MeSH terms
- Bayes Theorem, Chemistry, Clinical, Creatinine, Humans, Male, Multicenter Studies as Topic, Prostate-Specific Antigen, Research Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The European Biological Variation Study (EuBIVAS): a summary report. https://app.cochat.ai/papers/10.1515/cclm-2021-0370
- The paper
- Carobene, A., Aarsand, A. K., Bartlett, W. A., Coskun, A., Diaz-Garzon, J., Fernandez-Calle, P., Guerra, E., Jonker, N., Locatelli, M., Plebani, M., Sandberg, S., & Ceriotti, F. (2022). The European Biological Variation Study (EuBIVAS): a summary report. Clinical Chemistry and Laboratory Medicine (CCLM). https://doi.org/10.1515/cclm-2021-0370
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.